Published mark
Avalo Therapeutics, Inc.
NASDAQ: AVTX. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:9e35a6cd-d8ed-4c3d-8d64-3c4567650285
- SEC CIK
- 0001534120
- Record version
- vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- Apr 10, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Garry Neil, M.D.Since Mar 23, 2026
- Chair
- Not published
- Independent
- 6 / 77 directors published
- Published claims
- 263 distinct sources
- Evidence records
- 90 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CFO CHANGED
Christopher Sullivan executive of Avalo Therapeutics, Inc., effective 2026-03-23.
EffectiveEffective Mar 23, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Financial Officer | Christopher Sullivan | Mar 2026 | current | Source reportedE3 |
| Chief Executive Officer, President, Chairman of the Board | Garry Neil, M.D. | Mar 2026 | current | Source reportedE4 |
| Chief Strategy Officer | Jennifer Riley | Mar 2026 | current | Source reportedE5 |
| Chief Medical Officer | Mittie Doyle, M.D., FACR | Mar 2026 | current | Source reportedE6 |
| Chief Legal Officer | Paul Varki | Mar 2026 | current | Source reportedE7 |
| Chief Business Officer | Taylor Boyd | Mar 2026 | current | Source reportedE8 |
Board of directors
Evidence7 directors published. 6 of 7 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Aaron Kantoff | Independent | 2024 | Compensation, chairCompensation · Chair; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Garry Neil, M.D. | Not independent | 2022 | None published | Source reportedE2 |
| Gilla Kaplan, Ph.D. | Independent | 2020 | None published | Source reportedE2 |
| Kevin Lind | Independent | 2025 | Audit, chairAudit · Chair; CompensationCompensation | Source reportedE2 |
| Michael Heffernan | Independent | 2025 | None published | Source reportedE2 |
| Rita Jain, MD | Independent | 2025 | None published | Source reportedE2 |
| Samantha Truex | Independent | 2024 | CompensationCompensation; Nominating and Governance · ChairNominating and Governance, chair | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Kevin Lind | Kevin Lind | Not described in the published record |
| Audit · Chair; Compensation | Not published | Kevin Lind | Not described in the published record |
| Compensation | Aaron Kantoff | Aaron Kantoff, Kevin Lind, Samantha Truex | Not described in the published record |
| Compensation · Chair; Nominating and Governance | Not published | Aaron Kantoff | Not described in the published record |
| Compensation; Nominating and Governance · Chair | Not published | Samantha Truex | Not described in the published record |
| Nominating and Governance | Samantha Truex | Samantha Truex, Aaron Kantoff | Not described in the published record |
Committee RecordAudit: Chair Kevin Lind; Members Kevin Lind (Chair)
Committee AppointmentKevin Lind: chair, Audit
Committee RecordCompensation: Chair Aaron Kantoff; Members Aaron Kantoff (Chair); Kevin Lind; Samantha Truex
Committee AppointmentAaron Kantoff: chair, Compensation
Committee AppointmentKevin Lind: member, Compensation
Committee AppointmentSamantha Truex: member, Compensation
Committee RecordNominating and Governance: Chair Samantha Truex; Members Samantha Truex (Chair); Aaron Kantoff
Committee AppointmentSamantha Truex: chair, Nominating and Governance
Committee AppointmentAaron Kantoff: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerGarry Neil, M.D., Chief Executive Officer, President, Chairman of the Board, from Mar 23, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingAVTX (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameAvalo Therapeutics, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Christopher SullivanChief Financial Officercompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:12
- Garry Neil, M.D.Chief Executive Officer, President, Chairman of the Board; Directorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:13, company:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:6
- Jennifer RileyChief Strategy Officercompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:14
- Mittie Doyle, M.D., FACRChief Medical Officercompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:15
- Paul VarkiChief Legal Officercompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:16
- Taylor BoydChief Business Officercompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:17
- Aaron KantoffDirectorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:5
- Gilla Kaplan, Ph.D.Directorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:7
- Kevin LindDirectorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:8
- Michael HeffernanDirectorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:9
- Rita Jain, MDDirectorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:10
- Samantha TruexDirectorcompany:9e35a6cd-d8ed-4c3d-8d64-3c4567650285:leadership_role:11
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 10, 2026. Retrieved Apr 24, 2026. Cited by 7 Claims.
- E3sec filing. Published Mar 23, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E4sec filing. Published Mar 23, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E5sec filing. Published Mar 23, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E6sec filing. Published Mar 23, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E7sec filing. Published Mar 23, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E8sec filing. Published Mar 23, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E9board_seats. board seats. Cited by 9 Claims.
What changed in version public-1:ro-d751713988987e9331980363e24189ce
vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Christopher Sullivan executive of Avalo Therapeutics, Inc., effective 2026-03-23.
- Garry Neil, M.D. executive of Avalo Therapeutics, Inc., effective 2026-03-23.
- Jennifer Riley executive of Avalo Therapeutics, Inc., effective 2026-03-23.
- Mittie Doyle, M.D., FACR executive of Avalo Therapeutics, Inc., effective 2026-03-23.
- Paul Varki executive of Avalo Therapeutics, Inc., effective 2026-03-23.
- Taylor Boyd executive of Avalo Therapeutics, Inc., effective 2026-03-23.
- Kevin Lind seat on Avalo Therapeutics, Inc., effective 2025-01-01.
- Michael Heffernan seat on Avalo Therapeutics, Inc., effective 2025-01-01.
- Rita Jain, MD seat on Avalo Therapeutics, Inc., effective 2025-01-01.
- Audit · Chair; Compensation committee of Avalo Therapeutics, Inc., effective 2025-01-01.
- Kevin Lind member of Audit · Chair; Compensation, effective 2025-01-01.
- Aaron Kantoff seat on Avalo Therapeutics, Inc., effective 2024-01-01.
- Samantha Truex seat on Avalo Therapeutics, Inc., effective 2024-01-01.
- Compensation · Chair; Nominating and Governance committee of Avalo Therapeutics, Inc., effective 2024-01-01.
- Aaron Kantoff member of Compensation · Chair; Nominating and Governance, effective 2024-01-01.
- Compensation; Nominating and Governance · Chair committee of Avalo Therapeutics, Inc., effective 2024-01-01.
- Samantha Truex member of Compensation; Nominating and Governance · Chair, effective 2024-01-01.
- Garry Neil, M.D. seat on Avalo Therapeutics, Inc., effective 2022-01-01.
- Gilla Kaplan, Ph.D. seat on Avalo Therapeutics, Inc., effective 2020-01-01.